<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02005744</url>
  </required_header>
  <id_info>
    <org_study_id>19HI13018</org_study_id>
    <nct_id>NCT02005744</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function</brief_title>
  <official_title>A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function Compared With Normal Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate pharmacokinetics of CKD-501 in patients with
      impaired hepatic function compared with normal hepatic function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1, Non-randomized, Open, Parallel-Group study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration(last) and Cmax of CKD-501</measure>
    <time_frame>0 to 48 hours</time_frame>
    <description>Sampling timepoint(hours)
: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax, Area Under the Concentration(inf), T1/2 and Clearance/F of CKD-501 and its metabolite</measure>
    <time_frame>0 to 48 hours</time_frame>
    <description>Sampling timepoint(hours)
: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction Unbound of CKD-501 and its metabolite</measure>
    <time_frame>1 and 8 hours</time_frame>
    <description>sampling timepoint(hours)
: 1, 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration(last) and Cmax of the metabolite</measure>
    <time_frame>o to 48 hours</time_frame>
    <description>sampling timepoint(hours)
: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic ratio(metabolite/CKD-501)</measure>
    <time_frame>0 to 48 hours</time_frame>
    <description>sampling timepoint(hours)
: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Vital signs</measure>
    <time_frame>up to 8 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 8 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory tests</measure>
    <time_frame>up to 8 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 8 days</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Liver Dysfunction</condition>
  <arm_group>
    <arm_group_label>Child Pugh A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-501 will be administered to patients who are included Child Pugh A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Child Pugh B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-501 will be administered to patients who are included Child Pugh B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subject who are matched Child Pugh A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-501 will be administered to the Subjects who are matched Child Pugh A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subject who are matched Child Pugh B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-501 will be administered to the subjects who are matched Child Pugh B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-501</intervention_name>
    <description>CKD-501 0.5mg, PO(per oral), once</description>
    <arm_group_label>Child Pugh A</arm_group_label>
    <arm_group_label>Child Pugh B</arm_group_label>
    <arm_group_label>Subject who are matched Child Pugh A</arm_group_label>
    <arm_group_label>Subject who are matched Child Pugh B</arm_group_label>
    <other_name>Lobeglitazone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        A. Inclusion Criteria

        [The subjects with impaired hepatic function]

          1. The subjects who are 19 to 64 years old

          2. The subjects with stable hepatic disease and impaired hepatic function as Child-Pugh A
             or B

          3. Body Weight ≥ 55kg

          4. If females, Negative for pregnancy test at the screening and pre dose of Day 1

          5. The subjects who agreed with performing contraception during the study

          6. The subjects who agreed with written informed consent

        [The subjects with normal hepatic function]

          1. The subjects who are 19 to 64 years old

          2. The subjects who are matched impaired hepatic function by gender, age(± 5years) and
             body weight(± 10kg)

          3. If females, Negative for pregnancy test at the screening and pre dose of Day 1

          4. The subjects who agreed with performing contraception during the study

          5. The subjects who agreed with written informed consent

        B. exclusion criteria

        [The subjects with impaired hepatic function]

          1. The subjects with impaired hepatic function as Child-Pugh C

          2. The subjects had a portosystemic shunt surgery

          3. The subjects had a liver transplantation or unsuitable for the study by the
             investigator's judgement(for examples, hepatic encephalopathy grade 3 or 4, stroke,
             heart failure, cancer etc.) but The subject is eligible to participate if had not
             chemotherapy or radiofrequency ablation therapy within 6months)

          4. The subjects have a gastrointestinal disease or surgery which can be effected in
             absorption of Investigational product

          5. The subjects who took drugs or medicine which can be effected in metabolism of
             Cytochrome P450 within 14days prior to Day 1

          6. Positive for anti-HIV Ab or venereal disease research laboratory etc.

        [The subjects with normal hepatic function]

          1. The subjects with liver disease or abnormal Laboratory test(Asparate transaminase
             &gt;1.25 fold of upper normal limit, Alanine transaminase&gt;1.25 fold of upper normal
             limit, Total bilirubin &gt;1.5 fold of upper normal limit)

          2. The subjects have a gastrointestinal disease or surgery which can be effected in
             absorption of Investigational product

          3. Estimated Glomerular filtration rate &lt; 60 mL/min/1.73m2 by Modification of Diet in
             Renal Disease formula

          4. Positive for HBsAg, anti-Hepatitis C virus Ab, anti-HIV Ab or venereal disease
             research laboratory

          5. The subjects with high blood pressure or low blood pressure(systolic blood pressure
             &gt;150mmHg or &lt;100mmHg, diastolic blood pressure&gt;90mmHg or &lt;60mmHg)

          6. The subjects who took drugs or medicine which can be effected in metabolism of
             Cytochrome P450 within 14days prior to Day 1 etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Soo Park, Ph.D. M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei University Severance Hospital</name>
      <address>
        <city>Soeul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2013</study_first_submitted>
  <study_first_submitted_qc>December 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2013</study_first_posted>
  <last_update_submitted>July 1, 2016</last_update_submitted>
  <last_update_submitted_qc>July 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CKD-501</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

